Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
- Viganò, Mauro
- Loglio, Alessandro
- Labanca, Sara
- Zaltron, Serena
- Castelli, Francesco
- Andreone, Pietro
- Messina, Vincenzo
- Ganga, Roberto
- Coppola, Nicola
- Marrone, Aldo
- Russello, Maurizio
- Marzano, Alfredo
- Tucci, Alessandra
- Taliani, Gloria
- Fasano, Massimo
- Fagiuoli, Stefano
- Villa, Erica
- Bronte, Fabrizio
- Santantonio, Teresa
- Brancaccio, Giuseppina
- Occhipinti, Vincenzo
- Facchetti, Floriana
- Grossi, Glenda
- Rumi, Mariagrazia
- Lampertico, Pietro
Publication date
January 2018
DOIAbstract
Tenofovir disoproxil fumarate (TDF) is recommended for chronic hepatitis B (CHB) treatment, but it may induce kidney dysfunction whose management is not yet known. This Italian, multicentre, retrospective study aimed to assess the efficacy and safety of switching to entecavir (ETV) patients who developed TDF-associated glomerular and/or tubular dysfunction
Add to ORKG